Share
Rob Lauzen
Circle Pharma, Inc., a clinical-stage biopharmaceutical company developing breakthrough targeted macrocycle therapeutics for cancer, has appointed Rob Lauzen as its new Chief Financial Officer.
His appointment marks a significant enhancement to the company’s financial leadership as it advances its clinical pipeline and strengthens its position within the oncology innovation landscape.
Mr. Lauzen brings extensive financial expertise and a broad background in the life sciences sector. Most recently, he served as Chief Financial Officer at Prilenia Therapeutics, where he was responsible for shaping the company’s capital strategy, overseeing financial operations, and leading investor relations. His work was central to supporting Prilenia’s organizational growth and financing activities.
Before joining Prilenia, Mr. Lauzen served as Vice President of Investor Relations and Head of Financial Planning & Analysis at Dyne Therapeutics. In this role, he guided critical financial planning initiatives and built strong communication channels with the investment community, contributing to the company’s long-term strategic development.
Earlier in his career, Mr. Lauzen spent several years in the healthcare investment banking division at Morgan Stanley. There, he advised biopharmaceutical and healthcare clients on major strategic and financial decisions, executing more than US$185 billion in mergers and acquisitions and over US$10 billion in equity offerings. His deep understanding of capital markets and corporate growth strategies adds valuable perspective to Circle Pharma’s executive team.
Rob Lauzen holds a B.A. in Engineering Sciences from Dartmouth College. His appointment reinforces Circle Pharma’s commitment to building a strong financial foundation as it continues to deliver innovative cancer therapeutics.
